Skip to the beginning of the images gallery

Vonoprazan - 98%, high purity , CAS No.881681-00-1, Inhibitor of ATP4A

Moligand™

≥98%

CAS#: 881681-00-1
Formula: C₁₇H₁₆FN₃O₂S
Molecular Weight: 345.39
PubChem CID: 15981397

Item Number

V419367

Grouped product items
SKU	Size	Availability	Price
V419367-50mg	50mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$27.90
V419367-100mg	100mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$44.90
V419367-250mg	250mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$89.90
V419367-1g	1g	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$251.90

View related series

Anti-infection ATP4A Inhibitor Bacterial Membrane Transporter/Ion Channel Proton Pump Proton pump inhibitor

Basic Description

Synonyms	Vonoprazan (USAN/INN) \| {[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]methyl}(methyl)amine \| 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonyl-pyrrol-3-yl]-~{N}-methyl-methanamine \| AC-36443 \| TAK-438 free base \| vonoprazanum \| 4-hydroxy-4'-metho
Specifications & Purity	Moligand™, ≥98%
Storage Temp	Protected from light,Store at -20°C,Argon charged
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	Inhibitor of ATP4A
Product Description	Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori.

Names and Identifiers

IUPAC Name	1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
INCHI	InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3
InChi Key	BFDBKMOZYNOTPK-UHFFFAOYSA-N
Canonical SMILES	CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3
Isomeric SMILES	CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3
Alternate CAS	881681-00-1
PubChem CID	15981397
MeSH Entry Terms	1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine;TAK 438;TAK-438;TAK438;Vonoprazan
Molecular Weight	345.39

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

8 results found

Lot Number	Certificate Type	Date	Item
F2404164	Certificate of Analysis	Feb 28, 2024	V419367
F2404165	Certificate of Analysis	Feb 28, 2024	V419367
F2404166	Certificate of Analysis	Feb 28, 2024	V419367
F2404167	Certificate of Analysis	Feb 28, 2024	V419367
F2404168	Certificate of Analysis	Feb 28, 2024	V419367
F2404170	Certificate of Analysis	Feb 28, 2024	V419367
F2404171	Certificate of Analysis	Feb 28, 2024	V419367
F2404172	Certificate of Analysis	Feb 28, 2024	V419367

References

1. Arikawa Y, Nishida H, Kurasawa O, Hasuoka A, Hirase K, Inatomi N, Hori Y, Matsukawa J, Imanishi A, Kondo M et al.. (2012) Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).. J Med Chem, 55 (9): (4446-56). [PMID:22512618] [10.1021/op500134e]
2. Garnock-Jones KP. (2015) Vonoprazan: first global approval.. Drugs, 75 (4): (439-43). [PMID:25744862] [10.1021/op500134e]
3. Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, Karashima M, Otsuka K, Inatomi N. (2016) Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).. Adv Ther, 33 (7): (1140-57). [PMID:27287852] [10.1021/op500134e]
4. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. (2015) The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.. Aliment Pharmacol Ther, 42 (11-12): (1315-26). [PMID:26423447] [10.1021/op500134e]
5. Inatomi N, Matsukawa J, Sakurai Y, Otake K. (2016) Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.. Pharmacol Ther, 168 (13): (12-22). [PMID:27514776] [10.1021/op500134e]
6. Abe K, Irie K, Nakanishi H, Suzuki H, Fujiyoshi Y. (2018) Crystal structures of the gastric proton pump.. Nature, 556 (7700): (214-218). [PMID:29618813] [10.1021/op500134e]
7. Oshima T, Miwa H. (2018) Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.. J Neurogastroenterol Motil, 24 (3): (334-344). [PMID:29739175] [10.1021/op500134e]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

Vonoprazan - 98%, high purity , CAS No.881681-00-1, Inhibitor of ATP4A

Basic Description

Associated Targets(Human)

Associated Targets(non-human)

Mechanisms of Action